I work in a Oncology/Hematology department that is in a outpatient hospital facility. Our hospital system changed formulary from Procrit J0885 to Retacrit (bio-similar) Q5106 at the start of 2019. We are getting denials for payment for the Retacrit with use in Myelodysplastic Syndrome patients D46.9. Is anyone else having this same issue? The EOB's come back as "experimental use". Any help would be much appreciated.
Thanks!
Tammy
Thanks!
Tammy